An agonist antibody specific for CD40 induces dendritic cell maturation and promotes autologous anti-tumour T-cell responses in an in vitro mixed autologous tumour cell/lymph node cell model

Scandinavian Journal of Immunology

Volumn 65, Issue 5, 2007, Pages 479-486

  Hunter, T B ^a   Alsarraj, M ^a   Gladue, R P ^b   Bedian, V ^b   Antonia, S J ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CD40 LIGAND MONOCLONAL ANTIBODY; CP 870893; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL MATURATION; CONTROLLED STUDY; DENDRITIC CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOTHERAPY; LYMPH NODE; MOLECULAR MODEL; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR CELL;

ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIGENS, CD40; ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; HUMANS; LYMPH NODES; LYMPHOCYTE CULTURE TEST, MIXED; T-LYMPHOCYTE SUBSETS;

EID: 34247327043     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2007.01927.x     Document Type: Article

References (36)

1. Rosenberg SA. Identification of cancer antigens: impact on development of cancer immunotherapies. Cancer J 2000 6 (Suppl. 3 S200 7.
2. Romero P, Dunbar PR, Valmori D et al. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med 1998 188 : 1641 50.
3. Sahin U, Tureci O, Schmitt H et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci U S A 1995 92 : 11810 3.
4. Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998 4 : 321 7.
5. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995 13 : 688 96.
6. Kugler A, Stuhler G, Walden P et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 2000 6 : 332 6.
7. Salazar LG, Disis ML. Cancer vaccines: the role of tumor burden in tipping the scale toward vaccine efficacy. J Clin Oncol 2005 23 : 7397 8.
8. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998 392 : 245 52.
9. Caux C, Massacrier C, Vanbervliet B et al. Activation of human dendritic cells through CD40 cross-linking. J Exp Med 1994 180 : 1263 72.
10. Cella M, Scheidegger D, Palmer-Lehmann K, Lane P, Lanzavecchia A, Alber G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 1996 184 : 747 52.
11. Serra P, Amrani A, Yamanouchi J et al. CD40 ligation releases immature dendritic cells from the control of regulatory CD4+ CD25+ T cells. Immunity 2003 19 : 877 89.
12. Albert ML, Jegathesan M, Darnell RB. Dendritic cell maturation is required for the cross-tolerization of CD8+ T cells. Nat Immunol 2001 2 : 1010 7.
13. Mackey MF, Barth RJ Jr., Noelle RJ. The role of CD40/CD154 interactions in the priming, differentiation, and effector function of helper and cytotoxic T cells. J Leukoc Biol 1998 63 : 418 28.
14. Dessureault S, Alsarraj M, McCarthy S et al. A GM-CSF/CD40L producing cell augments anti-tumor T cell responses. J Surg Res 2005 125 : 173 81.
15. Chen Q, Daniel V, Maher DW, Hersey P. Production of IL-10 by melanoma cells: examination of its role in immunosuppression mediated by melanoma. Int J Cancer 1994 56 : 755 60.
16. Gabrilovich DI, Chen HL, Girgis KR et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996 2 : 1096 103.
17. Huang M, Wang J, Lee P et al. Human non-small cell lung cancer cells express a type 2 cytokine pattern. Cancer Res 1995 55 : 3847 53.
18. Menetrier-Caux C, Montmain G, Dieu MC et al. Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood 1998 92 : 4778 91.
19. Smith DR, Kunkel SL, Burdick MD et al. Production of interleukin-10 by human bronchogenic carcinoma. Am J Pathol 1994 145 : 18 25.
20. Steinbrink K, Jonuleit H, Muller G, Schuler G, Knop J, Enk AH. Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8(+) T cells resulting in a failure to lyse tumor cells. Blood 1999 93 : 1634 42.
21. Steinbrink K, Wolfl M, Jonuleit H, Knop J, Enk AH. Induction of tolerance by IL-10-treated dendritic cells. J Immunol 1997 159 : 4772 80.
22. Wahid R, Cannon MJ, Chow M. Dendritic cells and macrophages are productively infected by poliovirus. J Virol 2005 79 : 401 9.
23. Ramarathinam L, Castle M, Wu Y, Liu Y. T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells. J Exp Med 1994 179 : 1205 14.
24. Bai X-F, Bender J, Liu J, et al. Local costimulation reinvigorates tumor-specific cytolytic T lymphocytes for experimental therapy in mice with large tumor burdens. J Immunol 2001 167 : 3936 43.
25. Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 2005 54 : 721.
26. Colombo MP, Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002 13 : 155.
27. Chattopadhyay S, Chakraborty NG. Continuous presence of Th1 conditions is necessary for longer lasting tumor-specific CTL activity in stimulation cultures with PBL. Hum Immunol 2005 66 : 884.
28. Marcenaro E, Chiesa MD, Bellora F et al. IL-12 or IL-4 prime human NK cells to mediate functionally divergent interactions with dendritic cells or tumors. J Immunol 2005 174 : 3992 8.
29. Kusmartsev S, Gabrilovich D. Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol Immunother 2006 55 : 237.
30. Koch F, Stanzl U, Jennewein P et al. High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J Exp Med 1996 184 : 741 6.
31. Kiertscher SM, Luo J, Dubinett SM, Roth MD. Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells. J Immunol 2000 164 : 1269 76.
32. Peguet-Navarro J, Dalbiez-Gauthier C, Rattis FM, Van Kooten C, Banchereau J, Schmitt D. Functional expression of CD40 antigen on human epidermal Langerhans cells. J Immunol 1995 155 : 4241 7.
33. Sotomayor EM, Borrello I, Tubb E et al. Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat Med 1999 5 : 780 7.
34. Esche C, Gambotto A, Satoh Y et al. CD154 inhibits tumor-induced apoptosis in dendritic cells and tumor growth. Eur J Immunol 1999 29 : 2148 55.
35. Pirtskhalaishvili G, Shurin GV, Esche C et al. Cytokine-mediated protection of human dendritic cells from prostate cancer-induced apoptosis is regulated by the Bcl-2 family of proteins. Br J Cancer 2000 83 : 506 13.
36. Brossart P, Zobywalski A, Grunebach F et al. Tumor necrosis factor alpha and CD40 ligand antagonize the inhibitory effects of interleukin 10 on T-cell stimulatory capacity of dendritic cells. Cancer Res 2000 60 : 4485 92.